Outcome of the 34th Annual General Meeting held on 31 July 2026

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 31 July 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Outcome of 34th Annual General Meeting (“AGM”) Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) this is to inform that the AGM of the Company was held today, i.e., Friday, 31 July 2026, which commenced at 04:00 P.M. IST and ended at 05:50 P.M. IST. through Video Conferencing. The brief proceedings of the AGM are enclosed herewith as Annexure A and the transcript of the speech delivered at the AGM by Mr. Dilip Shanghvi, Executive Chairman, is enclosed herewith as Annexure B. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Annexure A Summary of proceedings of the 34th Annual General Meeting Held on 31 July 2026 The 34th Annual General Meeting (“AGM/ Meeting”) of the Company was held today, Friday, 31 July 2026, at 04:00 P.M. IST, through Video conferencing in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India from time to time. 1. The following resolutions were proposed for voting at the 34th AGM and have been approved by the shareholders with the requisite majority: S. N. Details of Resolution Resolution Type Ordinary Business: 1. Adoption of the Audited Standalone Financial Statements for the Ordinary financial year ended 31 March 2026, and the reports of the Board of Directors and Auditors thereon. 2. Adoption of the Audited Consolidated Financial Statements of the Ordinary Company for the financial year ended 31 March 2026, and the report of the Auditors thereon 3. Appointment of Mr. Aalok Shanghvi (DIN: 01951829), who retires Ordinary by rotation and being eligible, has offered himself for re- appointment 4. Declaration of the Final Dividend for the financial year 2025-26 of Ordinary Rs. 5.00/- per equity share Special Business: 5. Ratification of the Remuneration of M/s. Narasimha Murthy & Co., Ordinary Cost Accountants, Cost Auditors of the Company for FY 2026-27 6. Revision in Remuneration of Mr. Aalok Shanghvi (DIN: 01951829), Special Whole-time Director for the remaining tenure up to 31 May 2028 7. Approval for payment of commission to Independent Directors Ordinary within the limits prescribed under the Companies Act, 2013 8. Appointment of Dr. Andreas Busch (DIN: 11699735) as an Special Independent Director for a term of five consecutive years, from 12 May 2026 to 11 May 2031 2. Mr. Dilip Shanghvi, Executive Chairman of the Company, chaired the Meeting and, upon confirmation that the requisite quorum is present, conducted its proceedings. 3. All the Directors, Key Managerial Personnel and representatives of the Statutory Auditors, Secretarial Auditors and Cost Auditors participated in the AGM. 4. Remote e-voting was made available to the members from 27 July 2026 to 30 July 2026 for the resolutions set out in the Notice of AGM. Also, an e-voting facility was made available for the shareholders attending the meeting during the AGM and until 15 minutes after the conclusion of the AGM. 5. Mr. Chintan Goswami, Partner of KJB & CO LLP, acted as the Scrutinizer for the e-voting process. 6. The Chairman delivered his speech at the AGM. 7. Registered speaker shareholders were invited to ask questions/ queries, which were suitably addressed by Mr. Kirti Ganorkar, Managing Director of the Company. Annexure A Summary of proceedings of the 34th Annual General Meeting Held on 31 July 2026 8. The Scrutinizer was requested to submit the report to Mr. Anoop Deshpande, Company Secretary and Compliance Officer, who is authorised by the Chairman. 9. Mr. Anoop Deshpande, Company Secretary and Compliance Officer, proposed a vote of thanks to the Chair and with the Chairman's permission, declared the meeting concluded. ***** Annexure B Chairman Speech of the 34th Annual General Meeting Held on 31 July 2026 The global pharmaceutical industry continues to evolve rapidly, driven by innovation, expanding healthcare access, and increasing demand for specialty therapies. Global medicine spending is projected to reach approximately US$2.4 trillion by 2029, supported by broader adoption of innovative medicines, biologics, and treatments for chronic and complex diseases. Emerging markets such as India, Latin America, and parts of Asia remain important growth drivers, while innovation continues to create value across developed markets. Let me now share highlights of Sun Pharma's performance for FY26. Our consolidated revenues grew by 11.9% to ₹582 billion, reflecting broad-based growth across businesses and geographies. EBITDA increased by 16.1% to ₹177 billion, while adjusted net profit rose to ₹124 billion. Net worth strengthened to ₹836 billion, underscoring the resilience of our business model and strong cash-generation capabilities. We continued to invest in future growth, with R&D expenditure of ₹35.5 billion, representing 6.1% of sales. A defining feature of Sun Pharma's evolution has been the increasing contribution of Innovative Medicines and branded businesses. During FY26, Innovative Medicines accounted for 22% of consolidated sales and, for the first time, represented a larger share of US revenues than the US generics business. This milestone reflects years of disciplined investment in innovation. During the year, we strengthened our portfolio with the launches of LEQSELVI™ for severe alopecia areata and UNLOXCYT™ for advanced cutaneous squamous cell carcinoma in the United States. These additions reinforce our presence in dermatology, ophthalmology, and onco-dermatology. Today, we market 29 innovative medicines globally, serving patients across major international markets. India remains the cornerstone of our business and an important source of sustainable growth. During FY26, India revenues reached ₹193 billion, growing 14% and contributing approximately one-third of consolidated revenues. We maintained our position as India's largest pharmaceutical company with an 8.4% market share and continued prescription leadership across multiple specialties. Growth was primarily volume-led, supported by deeper doctor engagement, strong execution, expansion in Tier II and Tier III towns, and new product introductions. During the year, we launched ILUMYA® in India and entered the growing GLP- 1 segment with Noveltreat and Sematrinity, expanding treatment options for diabetes and weight management. Our US business continued to demonstrate resilience in a challenging operating environment. US revenues were ₹168 billion, accounting for 29% of consolidated sales. While the generics business faced pricing and compliance-related pressures, growth in Innovative Medicines offset these challenges. Performance from ILUMYA®, WINLEVI®, CEQUA®, and ODOMZO® continued to our growth in the US. Our Emerging Markets business delivered strong results, with revenues growing 18.8% to ₹112 billion. Growth was driven by solid performance across key markets, including in Brazil and Romania, supported by our branded generics and Innovative Medicines portfolios. Annexure B Chairman Speech of the 34th Annual General Meeting Held on 31 July 2026 The Rest of World business also reported strong growth, with revenues increasing 19.6% to ₹86 billion. The performance was led by Innovative Medicines, especially ILUMYA® and ODOMZO®, across important markets including Europe, Canada, Japan, and Australia. Subsequent to the close of the financial year, we ann [Showing first 8,000 characters — download PDF for full document]